Combination of cilostazol and clopidogrel attenuates Rat critical limb ischemia
© Sheu et al.; licensee BioMed Central Ltd. 2012
Received: 12 May 2012
Accepted: 25 July 2012
Published: 16 August 2012
Background and aim
Procedural failure and untoward clinical outcomes after surgery remain problematic in critical limb ischemia (CLI) patients. This study tested a clopidogrel-cilostazol combination treatment compared with either treatment alone in attenuating CLI and improving CLI-region blood flow in rats.
Male Sprague–Dawley rats (n = 40) were equally divided into five groups: control, CLI induction only, CL I + cilostazol (12.0 mg/day/kg), CLI + clopidogrel (8.0 mg/kg/day) and CLI + combined cilostazol-clopidogrel. After treatment for 21 days, Laser Doppler imaging was performed.
On day 21, the untreated CLI group had the lowest ratio of ischemic/normal blood flow (p < 0.001). Inflammation measured by VCAM-1 protein expression; oxidative stress; PAI-1, MMP-9 and TNF-α mRNA expressions; and immunofluorescence staining (IF) of CD68+ cells was lower with combined treatment than with the other treatments, and lower in the two single-treatment groups than the untreated CLI group (all p < 0.01). Anti-inflammatory mRNA expression of interleukin-10, and eNOS showed a reverse pattern among these groups. Apoptosis measured by Bax, caspase-3 and PARP; and muscle damage measured by cytosolic cytochrome-C, and serum and muscle micro-RNA-206 were all lowest with combination treatment, and the two single-treatment groups showed lower values than the untreated group (all p < 0.001). Angiogenesis measured by eNOS, IF staining of CD31+ and vWF + cells; and number of vessels in CLI region were highest with combination treatment and higher in the single-treatment groups than the untreated group (all p < 0.001).
Combined cilostazol-clopidogrel therapy is superior to either agent alone in improving ischemia in rodent CLI.
KeywordsCritical limb ischemia Apoptosis Inflammation Pharmacomodulation Angiogenesis
Some of the most important risk factors for atherosclerosis are hypercholesterolemia, hypertension, and diabetes mellitus. Peripheral arterial disease (PAD) is characterized by atherosclerotic occlusion of the lower extremities and is a common manifestation of systemic atherosclerosis . Patients with PAD have approximately the same relative risk of death from cardiovascular causes as those with a history of coronary or cerebrovascular disease , and patients with PAD may develop critical limb ischemia (CLI) at later stages of the disease [3, 4].
Treatment of CLI remains a formidable challenge to the clinician. Without appropriate treatment, the 1-year mortality rate can be as high as 25% . Bypass surgical intervention is one of the most popular and standard methods with the highest success rate, but procedural failure and short-term and long-term untoward clinical outcomes in some patients remain problematic. Failure to salvage CLI almost always leads to major limb loss which results in a major socio-economic burden. Therefore, development of more cost-effective treatments for patients with CLI and those unsuitable for either surgical or percutaneous intervention is urgently needed.
Clopidogrel, an adenosine diphosphatase (ADP) inhibitor, is currently used in acute arterial occlusive syndrome for inhibiting platelet activity and thrombus formation [6–9]. Additionally, cilostazol, a phosphodiesterase III inhibitor approved by the US Food and Drug Administration (FDA) for treatment of intermittent claudication, has been shown to have pleiotropic effects, including reducing smooth muscle proliferation, limiting intimal hyperplasia after endothelial injury, lowering restenotic rate of endovascular intervention, and inhibiting platelet activation and thrombus formation, as well as reducing inflammation [10–12]. Numerous clinical trials have shown that use of dual antiplatelet agents such as combined clopidogrel and aspirin are more effective than either one used alone for reducing future major adverse cardiac events in patients with acute coronary syndrome undergoing percutaneous coronary intervention [13–15]. However, whether combined cilostazol and clopidogrel therapy can offer similar additional benefit to improve PAD is currently unclear. This study used a rodent CLI model to explore the effects of a combined regimen of cilostazol and clopidogrel on ischemia in rodent CLI.
Materials and methods
All animal experimental procedures were approved by the Institute of Animal Care and Use Committee at Kaohsiung Chang Gung Memorial Hospital and performed in accordance with the Guide for the Care and Use of Laboratory Animals (NIH publication No. 85–23, National Academy Press, Washington, DC, USA, revised 1996).
Rationale for the dosage of combined cilostazol and clopidogrel
First, the safety and efficacy of different combinations of cilostazol and clopidogrel were compared. Six animals were used. They were assigned to receive low [cilostazol (8.0 mg/kg/day) and clopidogrel (4.0 mg/kg/day)], moderate [cilostazol (12.0 mg/kg/day) and clopidogrel (8.0 mg/kg/day)] or high [cilostazol (16.0 mg/kg/day) and clopidogrel (12.0 mg/kg/day)] dose regimens of this combined therapy. The high-dose regimen of this combined therapy easily induced wound swelling and bleeding after the CLI procedure. On the other hand, wound bleeding infrequently occurred in animals that received the moderate and low regimens of combined therapy. The blood flow in the CLI was markedly increased at the moderate dosage in comparison with that with the low dosage of this combined therapy. Therefore, the moderate dosage of the combined therapy, cilostazol (12.0 mg/kg/day) and clopidogrel (8.0 mg/kg/day), was used in subsequent experiments.
Male Sprague–Dawley rats (n = 40) were equally divided into five groups: group 1 (control), group 2 (CLI only), group 3 [CLI + cilostazol (12.0 mg/day/kg)], group 4 [CLI + clopidogrel (8.0 mg/kg/day)], and group 5 (combined cilostazol-clopidogrel) after CLI induction. All treatments were initiated just after the CLI procedure and continued for 21 days. The rats were sacrificed on day 21 after the Laser Doppler was performed.
Flow cytometric quantification of endothelial progenitor cells
Rats were anesthetized by intraperitoneal injections of isoflurane (2.0%) prior to CLI induction and at days 2 and 21 after CLI induction prior to be sacrificed. The rats were placed in a supine position on a warming pad at 37 °C and the blood flow were detected in both inguinal areas by a Laser Doppler scanner (moorLDLS, Moor, Co. UK). The ratio of flow in left (ischemic) leg and right (normal) leg was computed. The rats were sacrificed and the quadriceps muscle was collected for individual study.
Western blot analyses
Equal amounts (50 μg) of protein extracts were loaded and separated by SDS-PAGE using acrylamide gradients. After electrophoresis, the separated proteins were transferred electrophoretically to a polyvinylidene difluoride (PVDF) membrane (Amersham Biosciences). Nonspecific sites were blocked by incubation of the membrane in blocking buffer [5% nonfat dry milk in T-TBS (TBS containing 0.05% Tween 20) overnight. The membranes were incubated with the indicated primary antibodies [vascular cell adhesion molecule (VCAM)-1 (1:100, Abcam), cytochrome c (Cyt c) (1: 2000, BD), Bax (1: 1000, Abcam), caspase 3 (1:1000, Cell Signaling), poly(ADP-ribose) polymerase (PARP) (1:1000, Cell Signaling), endothelial nitric oxide synthase (eNOS) (1: 1000, Abcam), Actin (1: 10000, Chemicon )] for 1 hour at room temperature. Horseradish peroxidase -conjugated anti-rabbit immunoglobulin IgG (1: 2000, Cell Signaling) was used as a second antibody for one hour at room temperature. The washing procedure was repeated eight times within one hour, and immunoreactive bands were visualized by enhanced chemiluminescence (ECL; Amersham Biosciences) and exposure to Biomax L film (Kodak). For purposes of quantification, ECL signals were digitized using Labwork software (UVP).
Oxidative stress reaction of LV myocardium
The Oxyblot Oxidized Protein Detection Kit was purchased from Chemicon (S7150). DNPH derivatization was carried out on 6 μg of protein for 15 minutes according to manufacturer’s instructions. One-dimensional electrophoresis was carried out on 12% SDS/polyacrylamide gel after DNPH derivatization. Proteins were transferred to nitrocellulose membranes which were then incubated in the primary antibody solution (anti-DNP 1: 150) for 2 hrs, followed by incubation with second antibody solution (1:300) for 1 hr at room temperature. The washing procedure was repeated eight times within 40 minutes. Immunoreactive bands were visualized by enhanced chemiluminescence (ECL; Amersham Biosciences) which was then exposed to Biomax L film (Kodak). For quantification, ECL signals were digitized using Labwork software (UVP). For oxyblot protein analysis, a standard control was loaded on each gel.
Isolation of mitochondria from quadriceps
The skeletal muscle from ischemic region was excised and washed with buffer A (100 mM Tris–HCl, 70 mM sucrose, 10 mM EDTA and 210 mM mannitol, pH 7.4). The samples were first minced finely in cold buffer A and then incubated for 10 minutes at 4°C. All samples were then homogenized in an additional 3 mL of buffer A using a motor-driven grinder. The homogenate was centrifuged twice at 700 g for 10 minutes at 4°C. The supernatant was again centrifuged at 8,500 g for 15 minutes, and the pellets were then washed with buffer B (10 mM Tris–HCl, 70 mM sucrose, 1 mM EDTA, and 230 mM mannitol, pH 7.4). The mitochondria-rich pellets were finally collected and stored at −70°C for the individual study.
Real-time quantitative PCR analysis
Real-time reverse transcription polymerase chain reaction (RT-qPCR) was conducted using LighCycler TaqMan Master (Roche, Germany) in a single capillary tube according to the manufacturer’s guidelines for individual component concentrations. Forward and reverse primers were each designed in a different exon of the target gene sequence, eliminating the possibility for amplifying genomic DNA.
Total RNA was extracted using spin column-based RNA extraction kit (RNeasy Fibrous Tissue Mini Kit, Qiagen) according to protocols provided by manufacturer. Reverse transcriptions were performed with the Transcriptor First Strand cDNA Synthesis Kit (Roche). Briefly, 1 μg of total RNA was mixed with 50 pmole oligo dT and then incubated at 65°C for 10 minutes. After incubation on ice for 5 minutes, 4 μL of 5x reverse transcriptase reaction buffer, 0.5 μL of RNase inhibitor (40 U/μl), 2 μL of dNTP (10 mM for each), and 0.5 μL of reverse transcriptase (20 U/μL) were added into tubes containing hybridized RNA-oligo dT mixtures. RT reactions were carried at 55°C for 30 minutes. PCRs were performed on a Light Cycler (Roche Molecular Biochemicals). Each reaction was carried out with 1 μL of cDNA, 5 μL of 2x reaction mixtures (Maxima Probe qPCR Master Mix), 0.15 μL or each primer (20 μM), 0.2 μL of probe, and 3.5 μL of sterile distilled water. Reactions were performed by incubating in 95°C for 10 minutes, following with 45 cycles of 95°C for 10 sec, 60°C for 30 sec, and 72°C for 1 sec. Analysis of melting curves and determination of threshold cycle (Ct) were performed by the Light Cycler instrument’s software provided by Roche.
Immunofluorescent (IF) and immunohistochemical (IHC) studies
For IF staining, cryo-sections were fixed with cold acetone for 3 min and then incubated with primary antibody specifically against CD31 (1:200, Serotec) at 4°C overnight. After wash with PBS, sections were incubated Alexa Fluor 594-conjugated goat anti-mouse IgG secondary antibodies for 30 min at room temperature and followed by counter-staining with DAPI. Fluorescent signals were observed with fluorescent-equipped microscope (IX-41, Olympus).
For IHC staining, rehydrated paraffin sections were firstly treated with 3% H2O2 for 30 min and incubated with Immuno-Block reagent (BioSB) for 30 min at room temperature. Sections were then incubated with incubated with primary antibodies specifically against von Willebrand factor (vWF) (1:200, Millipore), at 4°C overnight. Irrelevant antibodies [(p53, 1: 500 (Abcam) and mouse control IgG (Abcam)] were used as controls in the current study. After washing with PBS thrice, the sections were incubated PolyDetector HRP Label (BioSB) for 30 min and washed with PBS thrice again. Finally, section were covered with DAB substrate-chromogen solution (BioSB) for 5 min and followed by counter-staining with hematoxylin. Three sections of muscle specimens were analyzed in each rat.
For quantification, three randomly selected HPFs (x100 for IHC stain and 400x for IF stain respectively) were analyzed in each section. The mean number per HPF for each animal was then determined by summation of all numbers divided by 9.
Vessel density in CLI region
IHC staining for determining the number of vessels was performed with primary antibody against α-SMA (1:400) with incubation at room temperature for one hour, followed by washing with PBS thrice. The anti-mouse-HRP conjugated secondary antibody was then added for 10 minutes, followed by washing with PBS thrice. Three ischemia sections were analyzed in each animal. For quantification, three randomly selected high-power fields (HPFs) (100x) were analyzed in each section. The mean number per HPF for each animal was then determined by summation of all numbers divided by 9.
Quantitative data are expressed as means ± SD. Statistical analysis was adequately performed by ANOVA followed by Bonferroni multiple-comparison post hoc test. Statistical analysis was performed using SAS statistical software for Windows version 8.2 (SAS institute, Cary, NC). A probability value <0.05 was considered statistically significant.
Combined cilostazol and clopidogrel treatment increases numbers of circulating EPCs in critical limb ischemia
Flow cytometric analysis was performed to investigate the effect of cilostazol and clopidogrel treatment on circulating endothelial progenitor cells (EPCs) at 18 h and on day 21 after the CLI procedure (Figure 1). Double staining for C-kit/CD31+ (Figure 1-A & B) and Sca-1/CD31+ (Figure 1-C to 1-D); and single staining for CXCR4+ (Figure 1-E & F) and CD34+ (Figure 1-G & H) were used.
At 18 h after the CLI procedure, the number of circulating C-kit/CD31+ cells (Figure 1-A) did not differ among the five groups. On day 21 after the procedure, the number of circulating C-kit/CD31+ cells (Figure 1-B) showed no significant difference between the untreated control group and the CLI only group, or between the control group and the two groups that received treatment with either cilostazol and clopidogrel; but, the number of circulating C-kit/CD31+ (Figure 1-B) cells was significantly higher in all the treatment groups (groups 3–5) than in the CLI group that received no treatment (group 2). Among the treatment groups the number of circulating C-kit/CD31+ cells (Figure 1-B) was notably higher in the group that received the combination therapy (group 5).
At 18 h after the CLI procedure, the number of circulating number of Sca-1/CD31+ cells (Figure 1-C) showed no significant difference between the control group, the CLI only group and the two groups receiving either cilostazol and clopidogrel treatment, or among groups 3 to 5, but was significantly higher in the group receiving the combination treatment (group 5) than in the control group or the CLI group (group 1) with no treatment (group 2). By day 21 after the procedure, the circulating level of these biomarkers revealed no difference among groups 1 to 4 or among groups 3 to 5 (Figure 1-D). However, this circulating biomarker level was still much higher in group 5 than in groups 1 and 2.
At 18 hours after the CLI procedure, the number of circulating CXCR4+ cells (Figure 1-E) displayed no difference between groups 1, 2 and 3, or between groups 4 and 5. However, there were significantly more circulating CXCR4+ cells in groups 4 and 5 than in groups 1, 2 and 3. By day 21 after the procedure, there was no significant difference among the five groups (Figure 1-F).
At 18 hours after the CLI procedure, there was no difference in the number of circulating CD34+ cells (Figure 1-G) among the five groups. By day 21 after the procedure (Figure 1-H), there was no difference in the number of circulating CD34+ cells among groups 1 to 4, but there was a significantly higher number in group 5 than in groups 1 to 4. Together these results suggest that combined cilostazol and clopidogrel treatment increases the number of circulating EPCs.
Combined cilostazol and clopidogrel treatment decreases inflammation and oxidation in critical limb ischemia
Combined cilostazol and clopidogrel treatment reduces skeletal muscle damage in critical limb ischemia
The protein expression of cytochrome C in mitochondria (Figure 4-D), an indicator of energy supply and storage in mitochondria, was significantly lower in the untreated CLI group (group 2) than in other groups, significantly lower in groups 3 to 5 than in the controls (group 1), but similar among groups 3, 4 and 5. In contrast, the protein expression of cytochrome C in the cytosol (Figure 4-E), an indicator of mitochondrial damage, was significantly higher in the untreated CLI group (group 2) than in other groups, significantly higher in groups 3 and 4 than in groups 1 and 5, and significantly higher in group 5 than in group 1, but it exhibited no difference between groups 3 and 4.
Combined cilostazol and clopidogrel treatment reduces apoptosis in critical limb ischemia
Cleaved caspase 3 (i.e., active form) was significantly higher in groups 2 than in other groups, significantly higher in groups 3 and 4 than in groups 1 and 5, higher in group 5 than in group 1, but it showed no difference between groups 3 and 4 (Figure 6-B). These results suggest that less apoptosis occurs in critical limb ischemia after combined cilostazol and clopidogrel treatment.
Combined cilostazol and clopidogrel treatment increases angiogenesis in the CLI region
Blood flow in the CLI region is improved with combined cilostazol and clopidogrel treatment
This study investigated the therapeutic effect of combined cilostazol and clopidogrel treatment on a murine model of CLI. Several observations were made: First, CLI without treatment markedly enhanced inflammation, oxidative stress, cellular apoptosis and tissue fibrosis in mice. Second, serum microRNA-206 level was a simple and useful biomarker for determining the skeletal muscle ischemia/damage. Third, cilostazol or clopidogrel therapy used alone showed similar effects on inflammation, oxidative stress, cellular apoptosis, ischemia-related muscle damage and tissue fibrosis, but combination treatment of these two drugs had a more pronounced suppressive effect than either agent used alone. Cilostazol and clopidogrel combination treatment was superior to either drug alone for enriching angiogenic factors and blood vessel density and improving blood flow in the ischemic area.
Inflammation and oxidative stress are two key factors thought to be associated with endothelial dysfunction, and consequent atherosclerosis, plaque rupture and acute arterial occlusive syndrome [17–20]. They are also increased [21–25] and play crucial roles in continued progressive damage to organs after acute ischemic attack [22, 25]. One important finding of the current study was that compared to the normal control, inflammation and oxidative-stress were substantially increased in rats after CLI, findings which support previous studies [21–25]. Inflammation and oxidative-stress were significantly suppressed after cilostazol or clopidogrel therapy. A previous study showed that cilostazol therapy markedly suppressed the expressions of the TNF-α and MMP-9, two indicators of inflammation, in lung parenchyma of pulmonary arterial hypertension rats . Additionally, our previous studies and those of others have shown that clopidogrel therapy significantly attenuated circulating levels of soluble CD40 ligand and high-sensitivity C-reactive protein (hs-CRP), two indicators of inflammation, and reduced oxidative stress [27–29]. However, the present study showed that combined cilostazol and clopidogrel therapy more markedly inhibited the inflammatory and oxidative-stress responses, thus, extending the findings of previous studies [26–29].
The association between ischemia and inflammation, and incremental cellular apoptosis and death is well known [24, 25, 29, 30]. In the current study, compared with the normal control, both mRNA and protein levels of apoptosis biomarkers were substantially increased in CLI animals; however, these apoptotic parameters were remarkably reduced in CLI animals after receiving cilostazol or clopidogrel therapy. Conversely, the anti-apoptotic biomarkers which were reduced in CLI animals were markedly upregulated in those CLI animals with cilostazol or clopidogrel therapy. Previous studies have also revealed the effect of cilostazol and clopidogrel therapy significantly inhibited the cellular apoptosis in ischemic tissues/organs [26, 29]. Combined therapy with these two agents further ameliorated apoptosis and enhanced the anti-apoptotic effect to a much greater extent than in either agent alone after CLI. Our findings further show that serum and ischemic muscle of levels of microRNA-206, an index of skeletal muscle damage, were further reduced; and mitochondrial cytochrome C and PGC-1α were more significantly preserved with combined cilostazol or clopidogrel therapy in comparison with either treatment used alone.
One particularly distinctive finding in the present study was that the circulating level of EPCs, the protein expression of eNOS, the number of small blood vessels and the numbers of CD31+ and vWF + cells (i.e., new endothelial cells) in CLI region were prominently increased in CLI animals with cilostazol or clopidogrel therapy. Combined treatment with cilostazol and clopidogrel was superior to either treatment used alone for enhancing exhibition of these angiogenic factors both in circulation and in the ischemic region. These findings may explain why the Laser Doppler results of blood flow in CLI area was significantly improved in animals that underwent monotherapy and further improved in animals receiving combined therapy in comparison to those animals without treatment. We have previously demonstrated that cilostazol therapy enhanced the eNOS mRNA expressions in both lung and right ventricle in a rat model of pulmonary arterial hypertension . Additionally, cilostazol has been previously shown to enrich vasculogenesis through enhancing EPC mobilization from bone marrow to circulation and promoting the production of angiogenic factors and chemokines [i.e., eNOS, CXCR4, vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1α]  for recruiting and mobilizing new EPCs/endothelial cells to ischemic region [31, 32]. The findings from these studies [26, 31, 32] have been reinforced by the results from another previous study  which has demonstrated that vardenafil, a PDE-5 inhibitor, enhanced ischemia-induced angiogenesis with mobilization of EPCs through a protein kinase G–dependent hypoxia-inducible factor (HIF)-1α/VEGF. Furthermore, it has previously been shown that clopidogrel therapy significantly increased the number of EPCs [34, 35]. Moreover, clopidogrel treatment in patients with coronary artery disease not only inhibits platelet activation but also improves endothelial function and nitric oxide bioavailability . Besides, study  has further displayed clopidogrel improved adenylyl cyclase-mediated signaling including increased Akt- and eNOS-phosphorylation contributing to improved NO-mediated vasorelaxation  and EPC mobilization[34, 35]. Accordingly, in addition to reinforcing these previous findings [26, 31–36], our results raise the possibility of using a combined regimen for CLI patients who are not candidates for bypass surgery and catheter-based intervention.
This study has several limitations. First, this study did not investigate the contribution of cilostazol or clopidogrel to anti-thrombosis and anti-platelet activity. Therefore, it is unclear whether reducing thrombosis and platelet activity would potentially contribute to increase in blood flow in the CLI area. Second, the underlying mechanism responsible for the upregulation of EPCs in circulation and the new endothelial cells in CLI region has not been explored in the current study. A previous study suggested that these changes could be due to mobilization from the bone marrow, or alternatively a decrease in the peripheral apoptotic destruction of EPCs . Third, the results of the current study did not address whether the mechanisms of cilostazol and clopidogrel therapy were the same or different and if the high dosage of cilostazol or clopidogrel might work as well as both of them in the moderate for increasing EPC number in circulation and generating eNOS and angiogenesis in ischemia area.
Kun-Chen Lin indicates equal contribution in this study compared with the first author.
Jenq-Lin Yang indicates equal contribution in this study compared with the correspondence author.
This study was supported by a program grant from Chang Gung Memorial Hospital, Chang Gung University (Grant number: CMRPG891501).
- Hiatt WR: Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 2001, 344: 1608-1621. 10.1056/NEJM200105243442108.View ArticlePubMed
- Newman AB, Shemanski L, Manolio TA, Cushman M, Mittelmark M, Polak JF, Powe NR, Siscovick D: Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol. 1999, 19: 538-545. 10.1161/01.ATV.19.3.538.View ArticlePubMed
- Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR: Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001, 286: 1317-1324. 10.1001/jama.286.11.1317.View ArticlePubMed
- Ouriel K: Peripheral arterial disease. Lancet. 2001, 358: 1257-1264. 10.1016/S0140-6736(01)06351-6.View ArticlePubMed
- Dormandy JA, Heeck L, Vig S: The fate of patients with critical leg ischemia. Semin Vasc Surg. 1999, 12: 142-147.PubMed
- Yip HK, Wu CJ, Hang CL, Chang HW, Hung WC, Yeh KH, Yang CH: Serial changes in platelet activation in patients with unstable angina following coronary stenting: evaluation of the effect of clopidogrel loading dose in inhibiting platelet activation. Circ J. 2005, 69: 1208-1211. 10.1253/circj.69.1208.View ArticlePubMed
- Yip HK, Chen SS, Liu JS, Chang HW, Kao YF, Lan MY, Chang YY, Lai SL, Chen WH, Chen MC: Serial changes in platelet activation in patients after ischemic stroke: role of pharmacodynamic modulation. Stroke. 2004, 35: 1683-1687. 10.1161/01.STR.0000131658.80951.c3.View ArticlePubMed
- Mehta SR, Yusuf S: Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J. 2000, 21: 2033-2041.View ArticlePubMed
- Hirsh J, Bhatt DL: Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. Arch Intern Med. 2004, 164: 2106-2110. 10.1001/archinte.164.19.2106.View ArticlePubMed
- Pan X, Arauz E, Krzanowski JJ, Fitzpatrick DF, Polson JB: Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isoenzyme families PDE III and PDE IV to attenuate proliferation rate of vascular smooth muscle cells. Biochem Pharmacol. 1994, 48: 827-835.View ArticlePubMed
- Kubota Y, Kichikawa K, Uchida H: Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries: an experimental study. Invest Radiol. 1995, 30: 532-537. 10.1097/00004424-199509000-00004.View ArticlePubMed
- Douglas JS, Holmes DR, Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, Morris DC, Liberman H, Parker K, Jurkovitz C, Murrah N, Foster J, Hyde P, Mancini GB, Weintraub WS: Cilostazol for Restenosis Trial (CREST) Investigators. Coronary stent restenosis in patients treated with cilostazol. Circulation. 2005, 112: 2826-2832. 10.1161/CIRCULATIONAHA.104.530097.View ArticlePubMed
- Sabatine MS, Hamdalla HN, Mehta SR, Fox KA, Topol EJ, Steinhubl SR, Cannon CP: Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. Am Heart J. 2008, 155: 910-917. 10.1016/j.ahj.2007.11.020.View ArticlePubMed
- Lemesle G, Torguson R, Bonello L, de Labriolle A, Maluenda G, Ben-Dor I, Collins SD, Syed AI, Xue Z, Satler LF, Pichard AD, Waksman R: Relation between clopidogrel discontinuation and early cardiovascular events after percutaneous coronary intervention with drug-eluting stents. Euro Intervention. 2011, 6: 1053-1059.PubMed
- Park DW, Yun SC, Lee SW, Kim YH, Lee CW, Hong MK, Cheong SS, Kim JJ, Park SW, Park SJ: Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents. JACC Cardiovasc Interv. 2008, 1: 494-503. 10.1016/j.jcin.2008.06.011.View ArticlePubMed
- Yip HK, Chang LT, Chang WN, Lu CH, Liou CW, Lan MY, Liu JS, Youssef AA, Chang HW: Level and value of circulating endothelial progenitor cells in patients after acute ischemic stroke. Stroke. 2008, 39: 69-74. 10.1161/STROKEAHA.107.489401.View ArticlePubMed
- Yip HK, Wu CJ, Chang HW, Yang CH, Yeh KH, Chua S, Fu M: Levels and values of serum high-sensitivity C-reactive protein within six hours after the onset of an acute myocardial infarction. Chest. 2004, 126: 1417-1422. 10.1378/chest.126.5.1417.View ArticlePubMed
- Yip HK, Sun CK, Chang LT, Wu CJ: Strong correlation between serum levels of inflammatory mediators and their distribution in infarct coronary. Circ J. 2006, 70: 838-845. 10.1253/circj.70.838.View ArticlePubMed
- van der Wal AC, Becker AE, van der Loos CM, Das PK: Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994, 89: 36-44. 10.1161/01.CIR.89.1.36.View ArticlePubMed
- Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med. 1999, 340: 115-126. 10.1056/NEJM199901143400207.View ArticlePubMed
- De Scheerder I, Vandekerckhove J, Robbrecht J, Algoed L, De Buyzere M, De Langhe J, De Schrijver G, Clement D: Post cardiac injury syndrome and an increased humoral immune response against the major contractile proteins (actin and myosin). Am J Cardiol. 1985, 56: 631-633. 10.1016/0002-9149(85)91024-0.View ArticlePubMed
- Frangogiannis NG, Smith CW, Entman ML: The inflammatory response in myocardial infarction. Cardiovasc Res. 2002, 53: 31-47. 10.1016/S0008-6363(01)00434-5.View ArticlePubMed
- Lambert JM, Lopez EF, Lindsey ML: Macrophage roles following myocardial infarction. Int J Cardiol. 2008, 130: 147-158. 10.1016/j.ijcard.2008.04.059.PubMed CentralView ArticlePubMed
- Leu S, Lin YC, Yuen CM, Yen CH, Kao YH, Sun CK, Yip HK: Adipose-derived mesenchymal stem cells markedly attenuate brain infarct size and improve neurological function in rats. J Transl Med. 2010, 8: 63-10.1186/1479-5876-8-63.PubMed CentralView ArticlePubMed
- Sheu JJ, Chua S, Sun CK, Chang LT, Yen CH, Wu CJ, Fu M, Yip HK: Intra-coronary administration of cyclosporine limits infarct size, attenuates remodeling and preserves left ventricular function in porcine acute anterior infarction. In J Cardiol. 2011, 147: 79-87.
- Sun CK, Lee FY, Sheu JJ, Yuen CM, Chua S, Chung SY, Chai HT, Chen YT, Kao YH, Chang LT, Yip HK: Early combined therapy with cilostazol and bone marrow-derived endothelial progenitor cells markedly attenuates pulmonary arterial hypertension in rats. J Pharmacol Exp Ther. 2009, 330: 718-726. 10.1124/jpet.109.154328.View ArticlePubMed
- Yip HK, Chang LT, Sun CK, Yang CH, Hung WC, Cheng CI, Chua S, Yeh KH, Wu CJ, Fu M: Impact of clopidogrel on suppression of circulating levels of soluble CD40 ligand in patients with unstable angina undergoing coronary stenting. Am J Cardiol. 2006, 97: 192-194. 10.1016/j.amjcard.2005.08.023.View ArticlePubMed
- Cekici Y, Korkmaz H, Celik A, Bilen MN, Bulut M, Akbulut M: The effect of the duration of clopidogrel use on hsCRP levels after stenting the target vessel in patients with acute coronary syndrome. Clin Invest Med. 2011, 34: E211-PubMed
- Hu H, Batteux F, Chereau C, Kavian N, Marut W, Gobeaux C, Borderie D, Dinh-Xuan AT, Weill B, Nicco C: Clopidogrel protects from cell apoptosis and oxidative damage in a mouse model of renal ischaemia-reperfusion injury. J Pathol. 2011, 225: 265-275. 10.1002/path.2916.View ArticlePubMed
- Tsai TH, Lin YC, Sun CK, Chung SY, Chai HT, Yang CH, Chen SM, Hang CL, Chen CJ, Chua S, Wu CJ, Leu S, Yip HK: Prognostic value of circulating dead monocytes in patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Cardiology. 2010, 117: 131-139. 10.1159/000320208.View ArticlePubMed
- Shin HK, Lee HR, Lee DH, Hong KW, Lee JH, Park SY, Lee SJ, Lee JS, Lee WS, Rhim BY, Kim CD: Cilostazol enhances neovascularization in the mouse hippocampus after transient forebrain ischemia. J Neurosci Res. 2010, 88: 2228-2238. 10.1002/jnr.22376.View ArticlePubMed
- Kawabe-Yako R, Masaaki I, Masuo O, Asahara T, Itakura T: Cilostazol activates function of bone marrow-derived endothelial progenitor cell for re-endothelialization in a carotid balloon injury model. PLoS One. 2011, 6: e24646-10.1371/journal.pone.0024646.PubMed CentralView ArticlePubMed
- Sahara M, Sata M, Morita T, Nakajima T, Hirata Y, Nagai R: A phosphodiesterase-5 inhibitor vardenafil enhances angiogenesis through a protein kinase G-dependent hypoxia-inducible factor-1/vascular endothelial growth factor pathway. Arterioscler Thromb Vasc Biol. 2010, 30: 1315-1324. 10.1161/ATVBAHA.109.201327.View ArticlePubMed
- Afek A, Kogan E, Maysel-Auslender S, Mor A, Regev E, Rubinstein A, Keren G, George J: Clopidogrel attenuates atheroma formation and induces a stable plaque phenotype in apolipoprotein E knockout mice. Microvasc Res. 2009, 77: 364-369. 10.1016/j.mvr.2009.01.009.View ArticlePubMed
- França CN, Pinheiro LF, Izar MC, Brunialti MK, Salomão R, Bianco HT, Kasmas SH, Barbosa SP, de Nucci G, Fonseca FA: Endothelial progenitor cell mobilization and platelet microparticle release are influenced by clopidogrel plasma levels in stable coronary artery disease. Circ J. 2012, 76: 729-736. 10.1253/circj.CJ-11-1145.View ArticlePubMed
- Schäfer A, Fraccarollo D, Pförtsch S, Loch E, Neuser J, Vogt C, Bauersachs J: Clopidogrel improves endothelial function and NO bioavailability by sensitizing adenylyl cyclase in rats with congestive heart failure. Basic Res Cardiol. 2011, 106: 485-494. 10.1007/s00395-011-0153-4.View ArticlePubMed
- Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, Janis LS, Lutsep HL, Barnwell SL, Waters MF, Hoh BL, Hourihane JM, Levy EI, Alexandrov AV, Harrigan MR, Chiu D, Klucznik RP, Clark JM, McDougall CG, Johnson MD, Pride GL, Torbey MT, Zaidat OO, Rumboldt Z, Cloft HJ: Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011, 365: 993-1003. 10.1056/NEJMoa1105335.PubMed CentralView ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.